Longitudinal clinical outcomes after the escalation of subcutaneous tocilizumab from every 2 weeks to once weekly in rheumatoid arthritis with inadequate disease control: A 52-week real-world observational study
- DOI
- 10.1186/s41927-026-00696-y
- Published
- 2026-09-25
- Container
- BMC Rheumatology
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1186/s41927-026-00696-y,
title = {Longitudinal clinical outcomes after the escalation of subcutaneous tocilizumab from every 2 weeks to once weekly in rheumatoid arthritis with inadequate disease control: A 52-week real-world observational study},
author = {Masanori Sudo and Sayuri Takamura and Asami Abe and Hajime Ishikawa and Daisuke Kobayashi and Kiyoshi Nakazono and Akira Murasawa and Suguru Yamamoto and Satoshi Ito},
year = {2026},
journal = {BMC Rheumatology},
doi = {10.1186/s41927-026-00696-y},
url = {https://doi.org/10.1186/s41927-026-00696-y}
}RIS
TY - JOUR TI - Longitudinal clinical outcomes after the escalation of subcutaneous tocilizumab from every 2 weeks to once weekly in rheumatoid arthritis with inadequate disease control: A 52-week real-world observational study AU - Masanori Sudo AU - Sayuri Takamura AU - Asami Abe AU - Hajime Ishikawa AU - Daisuke Kobayashi AU - Kiyoshi Nakazono AU - Akira Murasawa AU - Suguru Yamamoto AU - Satoshi Ito PY - 2026 JO - BMC Rheumatology DO - 10.1186/s41927-026-00696-y UR - https://doi.org/10.1186/s41927-026-00696-y ER -
APA
Sudo, M., Takamura, S., Abe, A., Ishikawa, H., Kobayashi, D., Nakazono, K., Murasawa, A., Yamamoto, S., & Ito, S. (2026). Longitudinal clinical outcomes after the escalation of subcutaneous tocilizumab from every 2 weeks to once weekly in rheumatoid arthritis with inadequate disease control: A 52-week real-world observational study. BMC Rheumatology. https://doi.org/10.1186/s41927-026-00696-y
Source records
- crossref · retrieved 2026-11-10T18:13:16.523Z